FDA Online Opioid Summit
Reducing the Availability of Opioids Online
Meeting Agenda
September 9, 2021
9:00 a.m. to 3:00 p.m. (ET), Zoom Virtual Platform

FDA Moderator
Douglas Throckmorton, M.D., Deputy Director for Regulatory Programs, Center for Drug Evaluation and Research (CDER), FDA

9:00 a.m.
Welcome and Introductory Remarks: Janet Woodcock, M.D., Acting Commissioner of Food and Drugs

9:15 a.m.
Successes and Solutions: Donald D. Ashley, J.D., Director, Office of Compliance, CDER

9:30 a.m.
Patient Health Impact: Panel Discussion
- Libby Baney, J.D., Senior Advisor, Alliance for Safe Online Pharmacies
- Shabbir J. Imber Safdar, Executive Director, Partnership for Safe Medicines
- Justin Macy, Pharm.D., J.D., Digital Health Senior Manager, National Association of Boards of Pharmacy

10:15 a.m.
Break

10:30 a.m.
Trends and Criminal Cases Updates: Daniel Burke, Chief, Investigative Services Division, Office of Criminal Investigations, FDA

10:45 a.m.
International Perspective: Matthew Nice, Manager, Global OPIOIDS Project, United Nations

11:00 a.m.
New and Novel Analytical Tools
- Timothy Mackey, MAS, Ph.D., U.C. San Diego
- Hui Zhao, Ph.D., Smeal College of Business, Pennsylvania State University

11:30 a.m.
Lunch

12:30 p.m.
Concurrent Roundtable Breakout Sessions
Moderators: S. Leigh Verbois, Ph.D., Director, Office of Drug Security, Integrity, and Response (ODSIR), CDER
    Sangeeta V. Chatterjee, Pharm.D., Deputy Director, ODSIR, CDER
- What are examples of stakeholder successes?
- What is the current and evolving landscape?
- What are the gaps and challenges?
- What are novel tools, technologies, and approaches to addressing the problem?

1:30 p.m.
Break

1:45 p.m.
Concurrent Roundtable Breakout Sessions (continued)

2:30 p.m.
Breakout Sessions Recap: S. Leigh Verbois, Ph.D.; Sangeeta V. Chatterjee, Pharm.D.

2:45 p.m.
Adjourn and Closing Remarks: Donald D. Ashley, J.D.